

Freedom of Information (Scotland) Act 2002

DATE RECEIVED	11/05/2022	SUBJECT	Medicines in Gastroenterology		
PASSED TO	Pharmacy	DATE PASSED	11/05/2022	RESPOND BY	01/06/2022
CATEGORY	Research	FoI NUMBER	2022-166		

Question/s to be Answered

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs?

- Adalimumab – Humira 1
- Adalimumab Biosimilar 13
- Filgotinib 0
- Golimumab 0
- Infliximab – Remicade 0
- Infliximab Biosimilar 0
- Ozanimod 0
- Tofacitinib 0
- Ustekinumab 0
- Vedolizumab 2

Q2 How many patients were treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilars
- Ustekinumab
- Vedolizumab

Unknown as we cannot differentiate the indications only where the prescriptions originate.